Orano Med is a clinical-stage biotechnology company and subsidiary of the Orano group specializing in nuclear medicine. It develops lead-212-based targeted alpha therapies for cancer and is expanding manufacturing capacities for lead-212 radiolabeled pharmaceuticals in North America and Europe.